Skip to main content

Table 5 Development history and application status of KRAS-G12C inhibitors

From: Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges

Name

Application date

Institutions

Structure

Status

Reference/ trial number

1_AM

August 2017

Dana-Farber Cancer Institute

Preclinical

[169]

Adagrasib

October 2019

Mirati

Clinical (approved)

[16]

NCT04685135; NCT03785249; NCT04330664; NCT04793958

ARS-853

January 2016

Memorial Sloan Kettering Cancer Center

Preclinical

[170]

ARS-1620

January 2018

Wellspring Biosciences

Preclinical

[171]

Compound 12

November 2013

University of California

Preclinical

[172]

D-1553

October 2020

InventisBio

Structure not disclosed

Clinical (recruiting)

NCT04585035

GDC-6036

June 2020

Genentech

Structure not disclosed

Clinical (recruiting)

NCT04449874

JNJ-74699157

July 2019

Araxes/J&J

Structure not disclosed

Clinical (terminated)

NCT04006301

LY3499446

November 2019

Eli Lilly

Structure not disclosed

Clinical (terminated)

NCT04165031

Sotorasib

October 2019

Amgen

Clinical (approved)

[15]

NCT04303780; NCT03600883; NCT04613596